IDEAS home Printed from https://ideas.repec.org/a/bpj/fhecpo/v18y2015i1p25-39n2.html
   My bibliography  Save this article

The Value of Delaying Alzheimer’s Disease Onset

Author

Listed:
  • Zissimopoulos Julie

    (Schaeffer Center for Health Policy and Economics, University of Southern California, 635 Downey Way, Los Angeles, CA 90089-3331, USA)

  • Crimmins Eileen

    (Davis School of Gerontology, University of Southern California, 3715 McClintock Ave., Los Angeles, CA, USA)

  • St.Clair Patricia

    (Schaeffer Center for Health Policy and Economics, University of Southern California, 635 Downey Way, Los Angeles, CA, USA)

Abstract

Alzheimer’s disease (AD) extracts a heavy societal toll. The value of medical advances that delay onset of AD could be significant. Using data from nationally representative samples from the Health and Retirement Study (1998–2008) and Aging Demographics and Memory Study (2001–2009), we estimate the prevalence and incidence of AD and the formal and informal health care costs associated with it. We use microsimulation to project future prevalence and costs of AD under different treatment scenarios. We find from 2010 to 2050, the number of individuals ages 70+ with AD increases 153%, from 3.6 to 9.1 million, and annual costs increase from $307 billion ($181B formal, $126B informal costs) to $1.5 trillion. 2010 annual per person costs were $71,303 and double by 2050. Medicare and Medicaid are paying 75% of formal costs. Medical advances that delay onset of AD for 5 years result in 41% lower prevalence and 40% lower cost of AD in 2050. For one cohort of older individuals, who would go on to acquire AD, a 5-year delay leads to 2.7 additional life years (about 5 AD-free), slightly higher formal care costs due to longer life but lower informal care costs for a total value of $511,208 per person. We find Medical advances delaying onset of AD generate significant economic and longevity benefits. The findings inform clinicians, policymakers, businesses and the public about the value of prevention, diagnosis, and treatment of AD.

Suggested Citation

  • Zissimopoulos Julie & Crimmins Eileen & St.Clair Patricia, 2015. "The Value of Delaying Alzheimer’s Disease Onset," Forum for Health Economics & Policy, De Gruyter, vol. 18(1), pages 25-39, January.
    • Handle: RePEc:bpj:fhecpo:v:18:y:2015:i:1:p:25-39:n:2
    DOI: 10.1515/fhep-2014-0013
    as

    Download full text from publisher

    File URL: https://doi.org/10.1515/fhep-2014-0013
    Download Restriction: For access to full text, subscription to the journal or payment for the individual article is required.
    File URL: https://libkey.io/10.1515/fhep-2014-0013?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Goldman Dana P & Zissimopoulos Julie & Lu Yang, 2011. "Medical Expenditure Measures in the Health and Retirement Study," Forum for Health Economics & Policy, De Gruyter, vol. 14(3), pages 1-33, April.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Douglas Barthold & Geoffrey Joyce & Roberta Diaz Brinton & Whitney Wharton & Patrick Gavin Kehoe & Julie Zissimopoulos, 2020. "Association of combination statin and antihypertensive therapy with reduced Alzheimer’s disease and related dementia risk," PLOS ONE, Public Library of Science, vol. 15(3), pages 1-15, March.
    2. Amitabh Chandra & Courtney Coile & Corina Mommaerts, 2023. "What Can Economics Say about Alzheimer's Disease?," Journal of Economic Literature, American Economic Association, vol. 61(2), pages 428-470, June.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Joelle H Fong, 2019. "Out-of-pocket health spending among Medicare beneficiaries: Which chronic diseases are most costly?," PLOS ONE, Public Library of Science, vol. 14(9), pages 1-16, September.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bpj:fhecpo:v:18:y:2015:i:1:p:25-39:n:2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Peter Golla (email available below). General contact details of provider: https://www.degruyter.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.